Physician profile
Stewart J Tepper
NPI 1912059221
$1,186,980.46
in general payments reported to CMS, 2019-2025
46 companies · $344K in 2025
The $344K reported for 2025 was more than what 99% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $120K · 2020: $79K · 2021: $108K · 2022: $91K · 2023: $210K · 2024: $236K · 2025: $344K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $295K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $242K · Honoraria: $120K · Travel and Lodging: $118K · Food and Beverage: $14K · Education: $26.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $294,765.25 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $242,461.23 |
| Honoraria | $120,184.75 |
| Travel and Lodging | $117,849.88 |
| Food and Beverage | $14,210.96 |
| Education | $26.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $311,934.35 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Pfizer INC. | $214,310.29 | 2023-2025 | |
| Lilly USA, LLC | $172,355.29 | 2019-2025 | Emgality, Amyvid |
| Axsome Therapeutics, INC. | $100,904.98 | 2025 | Symbravo |
| Amgen INC. | $93,369.96 | 2019-2025 | Aimovig, Uplizna |
| Eli Lilly and Company | $83,993.46 | 2019-2023 | Emgality |
| H. Lundbeck A S | $59,514.90 | 2021-2025 | Vyepti |
| Scilex Pharmaceuticals INC. | $23,677.57 | 2023-2024 | Elyxyb |
| Lundbeck LLC | $20,936.49 | 2019-2025 | Vyepti |
| Novartis Pharma Ag | $18,828.22 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $16,252.94 | 2020-2024 | Ajovy, Austedo Xr |
| Allergan, INC. | $15,500.00 | 2019-2020 | |
| Biodelivery Sciences International, INC. | $14,862.68 | 2019-2022 | |
| Currax Pharmaceuticals LLC | $8,220.12 | 2019-2020 | |
| Whitehall International INC | $8,000.00 | 2024 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd. | $5,725.44 | 2022 | |
| Tonix Medicines, INC. | $4,803.25 | 2023-2025 | Zembrace Symtouch |
| Bausch Health US, LLC | $4,717.50 | 2024-2025 | Aplenzin |
| Biohaven Pharmaceuticals, INC. | $3,000.00 | 2021 | |
| Pfizer International LLC | $2,000.00 | 2023 | |
| Biogen, INC. | $1,000.00 | 2019 | |
| Acorda Therapeutics, INC | $635.00 | 2019 | |
| Ipsen Innovation | $515.00 | 2023 | Dysport |
| Neurocrine Biosciences, INC. | $303.54 | 2023-2025 | Ingrezza, Ongentys |
| Csl Behring | $209.14 | 2023-2025 | Hizentra |
| Argenx US, INC. | $180.80 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Amneal Pharmaceuticals LLC | $171.30 | 2023-2025 | Crexont, Lyvispah, Ongentys 50mg Capsules 30 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $154.94 | 2023-2024 | Caplyta |
| Emd Serono, INC. | $154.61 | 2023-2025 | Mavenclad |
| Harmony Biosciences LLC | $108.33 | 2023-2024 | Wakix |
| Ucb, INC. | $98.23 | 2023-2025 | Nayzilam, Rystiggo |
| Ipsen Biopharmaceuticals, INC | $94.25 | 2023-2025 | Dysport |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.44 | 2023 | Relistor |
| Genentech USA, INC. | $61.65 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Impel Pharmaceuticals LLC | $60.08 | 2025 | Trudhesa |
| Sk Life Science, INC. | $54.23 | 2023-2024 | |
| Ani Pharmaceuticals, INC. | $36.06 | 2024 | Purified Cortrophin Gel |
| Corium, LLC | $32.99 | 2023-2024 | Azstarys |
| Abbott Laboratories | $26.55 | 2025 | Infinity |
| Eisai INC. | $23.10 | 2024 | |
| Octapharma USA, INC. | $22.86 | 2024 | Panzyga |
| Vertex Pharmaceuticals Incorporated | $21.73 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $21.53 | 2023 | Tezspire |
| Impel Pharmaceuticals INC. | $18.56 | 2023 | Trudhesa |
| Sumitomo Pharma America, INC. | $6.10 | 2023 | Aptiom |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$38,610.35 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stewart Tepper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.